
IP Group - visionary ventures
@ipgroupplc
Accelerating the impact of science for a better future with @ParkwalkAdvisor & @KikoVentures - @nanopore @FLFusion @FeaturespaceLtd #backinginnovation🧬🧪🔬🔭
ID: 335199434
http://www.ipgroupplc.com 14-07-2011 09:24:37
3,3K Tweet
5,5K Followers
2,2K Following

📈Greg Smith, CEO of IP Group - visionary ventures, in conversation with the Money Maze Curated Podcast about world class tech innovation in the UK and more Full interview out tomorrow via moneymazepodcast.com! #Finance #Investing #Economics #Business #AssetManagement #ad #Podcast #Interview



📈Today we welcome Greg Smith, CEO of IP Group - visionary ventures . He discusses: ✅ Why UK innovation remains world-class, and where to find it ✅ Their aim to help cure rheumatoid arthritis and hitherto deadly lung infections ✅ Automating airports, ports and warehouses via cutting edge AI



🔎💡A great read from Tech Funding News on European deeptech, featuring insight from Dr Lee Thornton, Partner here at IP Group - visionary ventures. Read the full article here: bit.ly/44iwhdD


👏 A huge congratulations to Australian portfolio company ElectraLith, which was selected a top innovator by the World Economic Forum! 🏆Electralith is a winner of the highly prestigious Sustainable Mining: Mining the Unmined Challenge. Read more: bit.ly/454TRL6






The NYSE welcomes Hinge Health to celebrate its IPO! #LetsGetMoving $HNGE x.com/i/broadcasts/1…


💬“Great companies are powered by the passion and authenticity of their originator.” Last week's IPO of portfolio company Hinge Health marks a significant milestone in a journey that began way back in 2012. In our latest Insight piece, Robert Trezona, Partner at IP Group - visionary ventures

🧬📰 Great news today from portfolio company Iksuda Therapeutics, which has announced the dosing of its first patient with IKS03, a CD19-directed antibody drug conjugate (ADC), in a phase 1, first-in-human, clinical trial in patients with advanced B cell non-Hodgkin lymphoma. 👉Read more:





🧬 A warm welcome to Dr Robert Tansley as portfolio company Microbiotica Ltd ’s Chief Medical Officer. The appointment comes at a key time for the company with its two lead programmes progressing through Phase 1 clinical trials in immuno-oncology (MB097 for advanced melanoma),
